Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - CymaBay Therapeutics, Inc. | d850210dex991.htm |
| EX-99.2 - EX-99.2 - CymaBay Therapeutics, Inc. | d850210dex992.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): January 12, 2015
CymaBay Therapeutics, Inc.
(Exact name of Registrant as specified in its charter)
| Delaware | 001-36500 | 94-3103561 | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
7999 Gateway Blvd., Suite 130
Newark, CA 94560
(Address of principal executive offices)
(510) 293-8800
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 7.01 | Regulation FD Disclosure. |
Attached as Exhibit 99.1 to this report, and incorporated herein by reference, is a slide presentation (the “Corporate Presentation”), which will be presented by CymaBay Therapeutics, Inc. at management presentations beginning Monday, January 12, 2015, to be held in San Francisco, California.
In accordance with General Instruction B.2. of Form 8-K, the information contained above in this Item 7.01 and the Corporate Presentation shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall the information or Corporate Presentation be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing. This Item 7.01 will not be deemed a determination or an admission as to the materiality of any information in the Corporate Presentation that is required to be disclosed by Regulation FD.
| Item 8.01 | Other Events. |
On January 12, 2015, the Company issued a press release announcing positive preliminary results from its Phase 2 clinical study of arhalofenate in combination with febuxostat. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.2 to this report, which is incorporated by reference.
| Item 9.01 | Financial Statements and Exhibits. |
| Exhibit | Description | |
| 99.1 | Arhalofenate Febuxostat Phase 2 PK/PD Study Presentation | |
| 99.2 | Press Release issued on January 12, 2015 | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| CymaBay Therapeutics, Inc. | ||
| By: | /s/ Sujal Shah | |
| Name: | Sujal Shah | |
| Title: | Chief Financial Officer | |
Dated: January 12, 2015
EXHIBIT INDEX
| Exhibit | Description | |
| 99.1 | Arhalofenate Febuxostat Phase 2 PK/PD Study Presentation | |
| 99.2 | Press Release issued on January 12, 2015 | |